Quick Answer
Black Diamond Therapeutics, Inc. reported Research And Development Expense of $33.56 million for the year ending 2025.
- Black Diamond Therapeutics, Inc. showed a decrease of -34.6% in Research And Development Expense from 2024 to 2025.
- This data is from Black Diamond Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $3.01 million | Q2 2019: $5.65 million | Q3 2019: $5.63 million | Q1 2020: $7.35 million | Q2 2020: $10.17 million | Q3 2020: $12.93 million | Q1 2021: $22.82 million | Q2 2021: $26.72 million | Q3 2021: $27.63 million | Q1 2022: $17.79 million | Q2 2022: $16.20 million | Q3 2022: $15.85 million | Q1 2023: $14.75 million | Q2 2023: $13.15 million | Q3 2023: $16.15 million | Q1 2024: $13.55 million | Q2 2024: $12.56 million | Q3 2024: $12.91 million | Q1 2025: $10.51 million | Q2 2025: $9.32 million | Q3 2025: $7.44 million.
- Over the full 8 years of available data (2018 to 2025), Black Diamond Therapeutics, Inc.'s Research And Development Expense has grown by 382.8%.
- Historical annual values: Fiscal year 2025: $33.56 million | Fiscal year 2024: $51.31 million | Fiscal year 2023: $59.35 million | Fiscal year 2022: $64.44 million | Fiscal year 2021: $96.83 million | Fiscal year 2020: $48.21 million | Fiscal year 2019: $21.75 million | Fiscal year 2018: $6.95 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: